Press Releases

InVivo Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update

Published: November 8, 2018

–  Announces Western Institutional Review Board Approval for Select INSPIRE 2.0 Study Sites – CAMBRIDGE, Mass. (November 8, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the quarter ended September 30, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “In the third quarter, we continued to focus efforts on and advance toward our top priority of initiating patient enrollment in the INSPIRE 2.0 study. We are pleased to announce that we have received Western Institutional Review Board (WIRB) approval for several sites in the INSPIRE 2.0 study. […]

View Article
InVivo Therapeutics Announces Joint Research Collaboration with Q Therapeutics, Inc.

Published: October 2, 2018

–  Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal Scaffold™ with stem cells – CAMBRIDGE, Mass. (Oct. 1, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced that it has entered into a joint research agreement with Q Therapeutics, Inc., a privately held developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury. The research collaboration is focused on the evaluation of the combination of InVivo’s proprietary PLGA-PLL based Neuro-Spinal Scaffold with Q Therapeutics’ adult […]

View Article
InVivo Therapeutics Announces Publication of Neuro-Spinal Scaffold Preclinical Data in Peer-Reviewed Journal Biomaterials

Published: October 1, 2018

–  Supports INSPIRE clinical investigation of the Neuro-Spinal Scaffold – CAMBRIDGE, Mass. (Oct. 1, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced the publication of a manuscript in the peer-reviewed journal Biomaterials describing preclinical findings regarding the Neuro-Spinal Scaffold.  The publication studied the clinical feasibility, timing and indication for scaffold implantation in a preclinical setting, and supports the scientific foundation for clinical investigation of biomaterial scaffold implantation into the human injured spinal cord. Richard Toselli, M.D., InVivo’s President and Chief […]

View Article
InVivo Therapeutics Announces Presentation at the Ladenburg Thalmann 2018 Healthcare Conference and Provides Business Update

Published: September 28, 2018

CAMBRIDGE, Mass. (Sept. 28, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New York.  Dr. Toselli’s presentation will discuss recent company updates, including updates related to the Company’s INSPIRE 2.0 Study. A live webcast will be available at http://wsw.com/webcast/ladenburg4/nviv/, and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 minutes […]

View Article
InVivo Therapeutics Announces Complete 12-Month Data from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

Published: August 28, 2018

CAMBRIDGE, Mass. (August 28, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the complete 12-month results from the company’s single-arm The INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). As previously announced by InVivo, 7 of 16 (44%) patients who reached the six-month primary endpoint visit in the INSPIRE study had an ASIA Impairment Scale (AIS) conversion at 6 months, which is the primary endpoint of the trial (defined as improvement in AIS grade from baseline for all evaluable patients at […]

View Article
InVivo Therapeutics Reports 2018 Second Quarter Financial Results

Published: August 7, 2018

–   Significant Increase in Operating Efficiency; Operating Expenses Decreased by 59% –   –   Progress on Initiation of INSPIRE 2.0 Study – CAMBRIDGE, Mass. (August 7, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a business update and reported financial results for the quarter ended June 30, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “We continued to make progress in the second quarter of 2018, as the net proceeds of $13.5 million from our successful June 2018 public offering have put us in a position to focus on the initiation of the INSPIRE 2.0 […]

View Article
InVivo Therapeutics Announces Closing of $15.2 Million Public Offering, Including the Exercise of Underwriter’s Overallotment Option

Published: June 25, 2018

CAMBRIDGE, Mass. (June 25, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and warrant.  In addition, the underwriter exercised its option to purchase […]

View Article
InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering

Published: June 21, 2018

InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering CAMBRIDGE, Mass. (June 21, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to an aggregate of 6,242,811 shares of common stock together with warrants to purchase 6,242,811 shares of common stock, at a combined price to the public of $1.99 per pre-funded warrant and […]

View Article
InVivo Therapeutics Reports 2018 First Quarter Financial Results

Published: May 7, 2018

Progress Update on INSPIRE 2.0 Trial, Finance Officer Appointment CAMBRIDGE, Mass. (May 7, 2018) – InVivo Therapeutics Holdings Corp. (NVIV) today provided a business and clinical update and reported financial results for the quarter ended March 31, 2018. Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo gained significant momentum in the first quarter of 2018, and we look forward to building on our positive momentum throughout the rest of the year.  We remain focused on the development of our Neuro-Spinal Scaffold™ and continue to take steps to reduce our expenses and maximize shareholder value.  Key spend […]

View Article
InVivo Therapeutics Announces Presentation of Complete Six-Month Primary Endpoint Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury

Published: May 2, 2018

– Findings Presented at the 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting – CAMBRIDGE, Mass. (May 2, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the presentation of the complete six-month primary endpoint results from the company’s single-arm The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at a medical meeting. The presentation was given by Stuart Lee, M.D., Division of Neurosurgery, Vidant Health, at the 2018 AANS Meeting during the Plenary Session II on Tuesday, May […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.